Heprion Inc.

Heprion Inc. is a biotechnology company developing next-generation gene therapies to treat prion and other neurodegenerative diseases at their root cause. Inspired by evolutionary resistance to prion and other neurodegenerative diseases, Heprion is engineering one-time intravenous therapeutic solutions designed to halt protein misfolding and aggregation. By combining insights from human genetics with advanced molecular engineering, Heprion aims to deliver durable, disease-modifying therapies for conditions that currently have none.

Contact: https://heprion.com/contact

Dr. Gerold Schmitt-Ulms,
Professor at University of Toronto, CEO of Heprion Inc
g.schmittulms@utoronto.ca

Dr. Hamza Arshad,
Postdoctoral Fellow at University of Toronto, CSO of Heprion Inc,
Hamza.arshad@alumni.utoronto.ca

Krembil Discovery Centre, 60 Leonard Avenue, Rm 4KD487,
Toronto, Ontario, Canada, M5T 0S8